pfizer glp-1 drug The next phase of the obesity race GLP-1 Medications for Weight Loss:

Pfizers dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron

Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity

Explore how nutrition can support natural GLP-1 production, a hormone key to blood sugar regulation and weight management, often targeted by popular weight loss medications

Updated 2025 GLP-1 guidelines for type 2 diabetes, including clinical insights, prescribing tips, and what healthcare providers need to know.

Mechanisms underlying long-term sustained weight loss and glycemic normalization after obesity surgery include changes in gut hormone levels, including glucagon-like peptide 1 (GLP-1) and peptide YY (PYY)